The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for metastatic pancreatic ductal adenocarcinoma in patients previously treated with chemotherapy, positioning it as the first RAS inhibitor cleared in this setting. The approval follows a phase 3 trial in which daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with chemotherapy in patients whose tumors carried relevant gene mutations. Industry focus now shifts to adoption and how quickly clinicians will place Rasonque into second-line treatment pathways for advanced PDAC. Revolution’s expedited path and the breadth of target coverage are likely to influence payer discussions and early prescribing behavior as the drug rolls out. Regulatory timing is also notable: the approval lands alongside a separate reporting cycle describing FDA priority review under its pilot program, underscoring continued FDA emphasis on faster review mechanisms for oncology drugs with defined molecular rationales.